Summary of Acinetobacter baumannii AB5075, version 29.0

Tier 2 Curated Organism Database

Database Authors

Lisa R. Moore¹, Varsha Naidu¹, Suzanne Paley², Ian T Paulsen¹, Peter D Karp²

¹Macquarie University, ²SRI International

Summary

Acinetobacter baumannii is considered the most important nosocomial species of the genus Acinetobacter [Peleg08] due to its antimicrobial resistivity. It is an oxidase-negative aerobe, coccobacillus, capable of non-flagellated motility and biofilm formation, and causes a range of both community and hospital-acquired infections. Some strains, capable of "escaping' the biocidal action of most antibiotics, are currently responsible for the majority of hospital infections in the U.S., placing them among the list of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) of major concern for public health [Boucher09]. Carbapenem-resistant Acinetobacter baumannii are also on the list of critical priority bacteria for investment in new drugs [Tacconelli18].

The phylogeny and taxonomy of Acinetobacter has changed significantly since its initial discovery in the early 20th century when it was originally designated as Micrococcus and subsequently reclassified as Acinetobacter in 1950 [Peleg08]. The species Acinetobacter baumannii was named and described in the mid-1980s with ATCC 19606 being designated as the type strain [Bouvet86].

A. baumannii infections and antibiotic resistance have increased in the early decades of the 21st century. Acinetobacter baumannii AB5075, a recent clinical isolate with multidrug resistance, high virulence in established animal models and the ability to be genetically manipulated, has become a model strain for studying the emerging pathogeneticity and antimicrobial treatments of A. baumanni [Jacobs14]. The genome of this model strain and its three plasmids were sequenced in 2015. Several unique features include an unusually small plasmid with only three genes and a novel resistance island on the largest plasmid [Gallagher15].

This Pathway/Genome Database (PGDB) was generated by the PathoLogic [Karp11, Karp16] component of Pathway Tools software version 24.5 and MetaCyc [Caspi18] version 24.1 on 06-Jun-2020. Development of this PGDB was supported by BioCyc subscription revenues and by grant GM080746 from the National Institute of Health.

Genome

Replicon	Total Genes	Protein Genes	RNA Genes	Pseudogenes	Size (bp)	NCBI Link
chromosome NZ_CP008706	3,863	3,695	130	38	3,972,672	NCBI Assembly:GCF_000963815.1
plasmid p1AB5075	105	101	0	4	83,610	NCBI Assembly:GCF_000963815.1
plasmid p2AB5075	10	10	0	0	8,731	NCBI Assembly:GCF_000963815.1
plasmid p3AB5075	2	2	0	0	1,967	NCBI Assembly:GCF_000963815.1

Total:	3,980	3,808	130	42	4,066,980

Ortholog data available?	Yes

Database Contents

Genes	3,981
Pathways	277
Enzymatic Reactions	1,339
Transport Reactions	29
Polypeptides	3,811
Protein Complexes	19
Enzymes	866
Transporters	415
Compounds	985
Transcription Units	2,809
tRNAs	74
Protein Features	4,561
GO Terms	2,800

Database Version

29.0

Synonyms	Acinetobacter baumannii AB5075 Acinetobacter genomospecies 2 Bacterium anitratum
Taxonomic Lineage	cellular organisms Bacteria <bacteria> Pseudomonadota Gammaproteobacteria Moraxellales Moraxellaceae Acinetobacter Acinetobacter calcoaceticus/baumannii complex Acinetobacter baumannii Acinetobacter baumannii AB5075
Genetic Code Number	11 -- Bacterial, Archaeal and Plant Plastid (same as Standard, except for alternate initiation codons)
BIOSAMPLE	SAMN02894434
NCBI BioProject	PRJNA224116
NCBI-Taxonomy	1116234
Environment	tibia/osteomyelitis of diabetes patient
Geographic Location	USA
Collection Date	2007-12-29/2008-12-29
Host	Homo sapiens
Human Microbiome Body Site	not-specified
Annotation Provider	NCBI RefSeq
Annotation Pipeline	NCBI Prokaryotic Genome Annotation Pipeline (PGAP)
Annotation Pipeline Version	4.11
Annotation Comment	Best-placed reference protein set; GeneMarkS-2+